

A systematic survey shows that reporting and handling of missing outcome data in networks of interventions is poor

Loukia M Spinelis¹; Juan Yepes-Nuñez^{2,3}; Holger Schünemann^{2,4}

Gefördert durch
DFG Deutsche
Forschungsgemeinschaft



Hannover Medical School

¹Institute for Biostatistics, Medical School of Hannover, Hannover, Germany

²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada

³School of Medicine, University of Antioquia, Medellin, Colombia

⁴Department of Medicine, McMaster University, Hamilton, Ontario, Canada

What is already known

Missing outcome data (MOD) in systematic reviews with meta-analysis are **poorly administrated** regarding¹⁻³:

- **Reporting** (*e.g. are there MOD in the included trials?*)
- **Handling** (*e.g. how the reviewers addressed MOD?*)
- **Acknowledging** (*MOD implications in the discussion of the results*)

1. **Gamble** C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. J Clin Epidemiol 2005;58:579–588.
2. **Spinelì** LM, Pandis N, Salanti G. Reporting and handling missing outcome data in mental health: A systematic review of cochrane systematic reviews and meta-analyses. Res Synth Methods 2015;6:175–87.
3. **Akl** EA, Carrasco-Labra A, Brignardello-Petersen R, et al. Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. BMJ Open 2015;5:e009368.

What is already known

Missing outcome data (MOD) in systematic reviews with meta-analysis are **poorly administrated** regarding¹⁻³:

- **Reporting** (*e.g. are there MOD in the included trials?*)
- **Handling** (*e.g. how the reviewers addressed MOD?*)
- **Acknowledging** (*MOD implications in the discussion of the results*)

Overall, **Cochrane and non-Cochrane reviews** are characterized by **inadequacies in reporting and handling MOD**.¹

1. **Akl** EA, Carrasco-Labra A, Brignardello-Petersen R, et al. Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. *BMJ Open* 2015;5:e009368.

What is currently unknown

A similar survey on **systematic reviews with network meta-analysis** (NMA) is missing



Expectations

- **Overall, poor quality** of reporting and addressing MOD in systematic reviews with NMA.

Search strategy



Published databases considered:

- Zarin et al. → **inception – 14/04/2015**; **≥ 4** interventions
- Tan et al. } → **1997 – 07/2012**; **≥ 3** interventions
- Bafeta et al. }
- Nikolakopoulou et al. → **inception – 12/2012**; **≥ 4** interventions

Our own search:

08/2012 – 03/2017; **≥ 3** interventions; using **Petropoulou et al.**
search strategy in MEDLINE, EMBASE and the CDSRs.

Eligibility strategy (1)



Following Zarin et al.:

- ✓ Systematic reviews of randomized controlled trials (RCTs);
- ✓ No language restriction;
- ✗ Diagnostic test accuracy studies;
- ✗ Genetic studies;
- ✗ Observational studies;
- ✗ Mixture of RCTs and observational studies;
- ✗ Number of included trials $<$ number of interventions.

Eligibility strategy (2)



Our own criteria:

- ✓ At least 3 interventions are investigated;
- ✓ Systematic reviews published from **2009 and onwards**;
 - ❖ *the new Cochrane risk of bias tool was published during 2009*
- ✗ RCTs with non-standard design;
 - ❖ *e.g. quasi, crossover, factorial, cluster, split-mouth.*
- ✗ Commentaries, letters, editorials;
- ✗ Case-series;

Eligibility strategy (3)




Our own criteria:

- ✓ At least 3 interventions are investigated;
- ✓ Systematic reviews published from **2009 and onwards**;
 - ❖ *the new Cochrane risk of bias tool was published during 2009*
- ✗ Protocols;
- ✗ Methodological articles relating to NMA;
- ✗ Overviews of systematic reviews;
- ✗ MOD investigated as single primary outcome.


Eligibility strategy (4)




For each eligible Systematic review:




*Akl EA, Kahale LA, Agarwal A, et al. Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. Syst Rev 2014;3:137



387 selected Systematic Reviews






**Non-Cochrane
reviews: 98%**

18%


24%

Addressing MOD in the

PROTOCOL




Addressing MOD in the **REVIEW**




*Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–758.

Addressing MOD in the **REVIEW**



Addressing MOD in the **REVIEW**



Addressing MOD in the **REVIEW**

Implications of MOD?

- **88 (32%) out of 273 reviews**

66% MOD as secondary
18% sensitivity analysis
12% MOD prevalence

Where reported mainly?


- **74 (84%) in Discussion**
- **46 (52%) in Abstract**

Which NMA components mainly?


- **84 (95%)** mixed effects;
- **13 (15%)** intervention ranking.

273 NMAs with present MOD

Network shape & Intervention-comparator type



Outcome type & Effect measure



Addressing MOD in the **NMA**

Strategy
explicitly
reported

- in 113 (40%) reviews only
 - 92% *claimed intention-to-treat*

60% as reported in trials
22% exclusion of MOD
17% intention-to-treat

Actual
strategy
judged

- agreed with 14 (12%) reviews
- able to judge in 95 (35%) reviews

Intention-to-
treat analysis
(16; 17%)

- 8 all MOD as non-events;
- 1 all MOD as events;
- 7 no scenario is provided.

Addressing MOD in the **NMA**

**Applied
sensitivity
analysis**

• **16 (6%) reviews only**

7 trial exclusion

5 available case analysis

3 imputation

Reported
any
changes

• **2 reviews only**

Justified strategy
used in primary &
sensitivity analysis

‘To carry out a clinically sound analysis, we used a conservative approach and imputed outcomes for the missing participants assuming that they did not respond to treatment’

• **12 out of 273** reviews

Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-58.

Strengths



- ✓ **First survey** on reporting and handling MOD in NMA.
- ✓ Systematic reviews from a **wide range of health fields**.
- ✓ **Multitude of sources** = 4 NMA databases + an update.
- ✓ **Comparable results** with our previous work¹.
- ✓ **Comparable results** with work by Akl and colleagues².

1. **Spineli** LM, Pandis N, Salanti G. Reporting and handling missing outcome data in mental health: A systematic review of cochrane systematic reviews and meta-analyses. Res Synth Methods 2015;6:175–87.
2. **Akl** EA, Carrasco-Labra A, Brignardello-Petersen R, et al. Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. BMJ Open 2015;5:e009368.

Limitations

Unleash Limitations



- **Several challenges** stemming from the poor reporting quality:
 - ☹ **Only 21%** of the reviews gave numerical **information on MOD**.
 - ☹ **Implicit information on MOD; mostly** via RoB tool.
 - ☹ We might have **underestimated the usage of LOCF**.
 - ☹ We **strived to judge** the actual method applied.

Conclusions - recommendations

- ❑ The **quality of reporting and handling MOD** in systematic reviews with NMAs is particularly inadequate!
- ❑ Reviewers remain **unaware of the presence and importance of MOD** in systematic reviews of multiple interventions.
- ❑ Poor handling of MOD attests to **limited knowledge of the reviewers** regarding the existing relevant methodology.
- ❑ **Education** amongst reviewers, peer reviewers and journal editors is deemed **necessary**!

References

Zarin W, Veroniki AA, Nincic V, et al. Characteristics and knowledge synthesis approach for 456 network meta-analyses: a scoping review. BMC Med 2017;15:3.

Tan SH, Bujkiewicz S, Sutton A, et al. Presentational approaches used in the UK for reporting evidence synthesis using indirect and mixed treatment comparisons. J Health Serv Res Policy 2013;18:224–32.

Bafeta A, Trinquart L, Seror R, Ravaud P. Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. BMJ 2013;347:f3675.

Nikolakopoulou A, Chaimani A, Veroniki AA, et al. Characteristics of networks of interventions: A description of a database of 186 published networks. PLoS One 2014;9:1–10.

Petropoulou M, Nikolakopoulou A, Veroniki AA, et al. Bibliographic study showed improving statistical methodology of network meta-analyses published between 1999 and 2015. J Clin Epidemiol 2017;82:20–28.

Thank you for your attention!

Examples of systematic reviews with explicit, implicit and unclear judgments

Explicit judgment of the actual method
<i>Available case analysis with or without LOCF</i>
'All analyses were based on the intention-to-treat (ITT) data reported in the manuscripts published for the included RCTs'. By comparing Appendix B (it gives information on randomized and completers sample) with Table 1, totals in latter are smaller in all studies.
<i>Imputation with or without LOCF</i>
'Responders to treatment were calculated on an intention-to-treat basis [...] imputed outcomes for the missing participants assuming that they did not respond to treatment'.
<i>Combination of Imputation and Available case analysis</i>
'[...] and results from intention-to-treat (ITT) analyses that included all randomized patients took precedence over results from analyses that excluded patients'. According to Table 1, some trials offered intention-to-treat whereas others either available case analysis or not a clear analysis method.

Examples of systematic reviews with explicit, implicit and unclear judgments

Implicit judgment of the actual method
<i>Available case analysis with or without LOCF</i>
Studies that employed LOCF have been reported in the quality assessment as having done intention-to-treat (see, Appendix 4 and Appendix 3).
<i>Imputation with or without LOCF</i>
Number randomized equals number analyzed but there is no reference to LOCF. All included trials applied intention-to-treat analysis (according to RoB table).
<i>Combination of Imputation and Available case analysis</i>
By comparing Table 1 (number randomized) with Figure 1 (number analyzed), some trials might have applied intention-to-treat analysis (without information on the imputation) and others available case analysis. No information on how trials or the reviewers handled missing outcome data.

Examples of systematic reviews with explicit, implicit and unclear judgments

Unclear judgment of the actual method

There is no information available on the analyzed and randomized sample for each trial as well as no information on how MOD have been handled in each trial. The reviewers don't report how they planned to handle missing outcome data.

The reviewers report that they employed intention-to-treat analysis. Information on randomized sample is provided but there is no information available on analyzed sample to judge whether intention-to-treat analysis is genuine.

Description of intention-to-treat analyses according to reports in reviews

Data extracted as reported in the trials

'Analyses were performed on data that were explicitly reported in the individual papers, with no imputations for data that were not reported. When available, we analysed the ITT population; when this was not possible, we used data from LOCF'.

Intention-to-treat analysis applied de novo

'Responders to treatment were calculated on an ITT basis [...] imputed outcomes for the missing participants assuming that they did not respond to treatment'.

Combination of *as reported* and *de novo* intention-to-treat analysis

'[...] according to the number of events reported in the original studies or sub-studies ITT analyses. Where studies did not report ITT, we analyzed outcomes as all-patients randomized'.

Unclear classification

'Our analysis was based on intention-to-treat principle.' (No information on whether intention-to-treat is as reported or de novo).